

cbdx

The Medical Cannabis and Wellness UCITS ETF - Acc

Factsheet | Data as of 31 May 2020

Investment Objective

The Medical Cannabis and Wellness UCITS ETF, is a UCITS compliant Exchange Traded Fund domiciled in Ireland. The Fund tracks an index designed to measure the performance of an investable universe of publicly listed companies with significant business activities in the medical cannabis, hemp and CBD industry.

Why CBDX?



Efficient:

In a single trade, CBDX provides access to a basket of companies from Developed and Emerging markets with high exposure to the medical cannabis, hemp and cannabinoids (CBD) industry.



Unique:

The only UCITS ETF to provide targeted exposure to a new and growing industry of companies engaged in the production and associated services and products in the medical cannabis industry



Diversification:

CBDX avoids concentration in larger stocks by capping constituent weights at 10% during the quarterly rebalance

Key Risks

1. The Sub-Fund and the companies in which it invests may be subject to a higher degree of regulatory oversight and regulatory action, which may include a restriction on the types of companies that the Sub-Fund may invest in at any time.
2. If a company becomes delisted from an exchange due to non-compliance with the rules and policies of the exchange, the Investment Manager will use reasonable endeavours to remove the company from the Sub-Fund's portfolio.
3. The value of equities and equity-related securities can be affected by daily stock and currency market movements.
4. Investors' capital is fully at risk and investors may not get back the amount originally invested
5. Exchange rate fluctuations could have a negative or positive effect on returns

Performance vs Index

Fund	1M	3M	6M	YTD	12M
CBDX	15.19%	11.21%	N/A	N/A	N/A
MEDCAWEN	15.25%	10.93%	-7.04%	-0.63%	-31.43%

Source: Bloomberg, as of 31 May 2020. Performance for the fund and the index is shown in USD. Fund performance is shown net of fees with income reinvested where applicable. Please be aware that fees have a detrimental impact on the performance of an ETP. Past performance is not an indicator for future results.

Contact

+44 (0)20 3794 1800
info@HANetf.com

HANetf Ltd, City Tower, 40 Basinghall St,
London, EC2V 5DE

Trading Information

Exchange	Ticker	RIC	SEDOL	ISIN	CCY
LSE	CBDX LN	CBDX.L	BGSXSL9	IE00BG5J1M21	USD
LSE	CBDP LN	CBDP.L	BGSXQX7	IE00BG5J1M21	GBP
Xetra	CBSX GY	CBSX.DE	BJBL4D5	DE000A2PPQ08	EUR
SIX	CBDX SW	CBDX.S	BMYC3S4	IE00BG5J1M21	CHF

Key Facts

Inception Date	09/01/2020
Index	Medical Cannabis and Wellness Equity Index
Asset Class	Equities
Number of Holdings	13
Base Currency	USD
Index Dividend Yield (Est)	0.63%
Income Treatment	Accumulating
TER	80 bps
Rebalance Frequency	Quarterly, last business day in February, May, August and November
Fund Domicile	Ireland
Replication Style	Physical
Registered for Sale	UK, IT, DE, IE, NL, FI, AT, CH
Fund Reporting Status	Yes
UCITS Compliant	Yes
UK SIPP Eligibility	Yes
UK ISA Eligibility	Seeking
Custodian	BNY Mellon
Portfolio Manager	Penserra Capital Management, LLC
Net Assets of Fund	8,823,168.16 (USD)
Net Assets of Share Class	8,823,168.16 (USD)
Shares Outstanding	1,118,000

cbdx

The Medical Cannabis and Wellness UCITS ETF - Acc

Factsheet | Data as of 31 May 2020

Index Information

The Medical Cannabis and Wellness Equity Index is calculated by Solactive AG, and follows a rules-based methodology to measure the performance of an investable universe of publicly listed companies with significant business activities in the legal medical cannabis, hemp and CBD industries. The index methodology embeds a rigorous multi-stage screening process take into account the relevant legal requirements when buying and holding securities in this sector.

Index Performance and Volatility Indicators (USD)

Period	Return	Volatility
2019	-8.06%	29.39%
2020	0.73%	51.37%


*Index data up to the 08/01/2020. Fund data from 09/01/2020

Performance before inception is based on back tested data. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of that strategy would have been. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. Past performance for the index is in USD and shown net of fees. Past performance and back tested index performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. It is provided for illustrative purposes only. Indices cannot be invested in directly. Investors should read the prospectus of the Issuer ("Prospectus") before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product. Source: Bloomberg / HANetf.

Top 10 Index Holdings (%)

Company	(%)	Company	(%)
Corbus Pharmaceuticals Holding	14.19%	Innovative Industrial Properti	8.08%
Scotts Miracle-Gro Co/The	12.16%	Charlottes Web Holdings Inc	8.06%
GW Pharmaceuticals PLC	10.81%	GrowGeneration Corp	6.25%
Cara Therapeutics Inc	9.52%	Zynerba Pharmaceuticals Inc	4.23%
Amyris Inc	9.27%	22nd Century Group Inc	3.82%

Regional Exposure



ETF Partner

The Medical Cannabis and Wellness UCITS ETF has been developed by HANetf, and Purpose Investments, a leading Canada-based asset manager. www.purposeinvest.com

About HANetf

HANetf is an independent provider of UCITS ETFs, working with asset management companies to bring differentiated, modern and innovative exposures to European ETF investors. Via our white-label ETF platform, HANetf provides a complete operational, regulatory, distribution and marketing solution for asset managers to launch and manage UCITS ETFs.

Contact

IMPORTANT INFORMATION

This factsheet is approved for professional use only. The fund to which it relates is a UCITS fund and accordingly is available for purchase by all investor types, including retail and professional investors. The content in this document is issued by HANetf Limited ("HANetf"), an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority ("FCA"). For professional clients only. Past performance is not a reliable indicator of future performance. Any historical performance included on this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided on this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements.

Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. These products may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment. An investment in an ETF is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETFs involve numerous risks including among others, general market risks relating to the relevant underlying index, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

The information contained on this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the Issuers or their products are authorised or registered for distribution and where no prospectus of any of the Issuers has been filed with any securities commission or regulatory authority. No document or information on this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the Issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes. The products discussed on this document are issued by HANetf ICAV.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements. HANetf ICAV is an open-ended Irish collective asset management vehicle which is constituted as an umbrella fund with segregated liability between sub-funds and with variable capital organised under the laws of Ireland and authorised by the Central Bank of Ireland ("CBI"). Investors should read the prospectus of HANetf ICAV ("HANetf Prospectus") before investing and should refer to the section of the HANetf Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the Shares.

RISK FACTORS

While the general risk factors set out in the section entitled Risk Factors in the Prospectus apply to the SubFund, the following risk factors described in the Prospectus under the headings Absence of prior active market, Capital Controls and Sanctions Risk, Concentration Risk, Emerging Market Risks, Currency Risk, Interest Rate Risk, Liquidity of Investments, Small- and Mid-Capitalisation Risk, Political and/or Legal/Regulatory Risk, Regulatory Restrictions, Index Rebalancing and Costs Risk and Issuer-specific Risk are particularly relevant for the Sub-Fund. In addition, the following to the above, the following risk is also relevant to this Sub-Fund: 9.1 Sectoral Investment Risk To the extent the SubFund invests a significant portion of its assets in the securities of companies of a sector, it is more likely to be impacted by events or conditions affecting that sector. The Sub-Fund may invest a relatively large percentage of its assets in sectors, including the consumer discretionary sector, the information technology sector and the financial sector, which sectors have tended to form a relatively large percentage of the Index. Further details of the specific risk relevant to these sectors are set out below.

Consumer Discretionary Sector Risk:

This sector consists of, for example, automobile, media and retail companies. The consumer discretionary sector of the economy can be significantly affected by, among other things, economic growth, worldwide demand and consumers' disposable income levels and propensity to spend.

Information Technology Sector Risk:

This sector can be significantly affected by, among other things, the supply and demand for specific products and services, the pace of technological development and government regulation. Challenges facing companies in the information technology sector include distressed cash flows due to the need to commit substantial capital to meet increasing competition, particularly in formulating new products and services using new technology, technological innovations that make existing products and services obsolete, and satisfying consumer demand.

FOR SWISS INVESTORS ONLY: The Fund has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: info@oligofunds.ch. The Fund's Swiss paying agent is Helvetische Bank AG. The Prospectus, the Key Investor Information Documents, the Instrument of Incorporation as well as the annual and semi-annual reports may be obtained free of charge from the Swiss Representative in Lausanne. In respect of the Shares distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the Swiss Representative. The issue and redemption prices are published at each issue and redemption on www.fundinfo.com This key investor information is accurate as at 1 May 2020.

Contact